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Abstract—Research in diabetes, especially when it comes to
building data-driven models to forecast future glucose values, is
hindered by the sensitive nature of the data. Because researchers
do not share the same data between studies, progress is hard
to assess. This paper aims at comparing the most promising
algorithms in the field, namely Feedforward Neural Networks
(FFNN), Long Short-Term Memory (LSTM) Recurrent Neural
Networks, Extreme Learning Machines (ELM), Support Vector
Regression (SVR) and Gaussian Processes (GP). They are person-
alized and trained on a population of 10 virtual children from
the Type 1 Diabetes Metabolic Simulator software to predict
future glucose values at a prediction horizon of 30 minutes. The
performances of the models are evaluated using the Root Mean
Squared Error (RMSE) and the Continuous Glucose-Error Grid
Analysis (CG-EGA). While most of the models end up having
low RMSE, the GP model with a Dot-Product kernel (GP-DP), a
novel usage in the context of glucose prediction, has the lowest.
Despite having good RMSE values, we show that the models do
not necessarily exhibit a good clinical acceptability, measured by
the CG-EGA. Only the LSTM, SVR and GP-DP models have
overall acceptable results, each of them performing best in one
of the glycemia regions.
Index Terms—Glucose prediction, Feedforward Neural Net-
work, Recurrent Neural Network, Long Short-Term Memory,
Extreme Learning Machine, Support Vector Regression, Gaus-
sian Process
I. INTRODUCTION
With 1.5 milion inputed deaths in 2012 [1], diabetes is
one of the most threatening diseases of the modern world.
Because of the non secretion of insulin (type-1 diabetes) or
body resistance to its action (type-2 diabetes), diabetic people
have trouble managing their blood glucose. When his blood
glucose falls too low, the diabetic is said to be in a state of
hypoglycemia, while, in the other hand, when it gets too high,
we talk about hyperglycemia. Because both hypoglycemia and
hyperglycemia have respectively short-term (e.g., exhaustion,
coma, death) and long-term (e.g., cardiovascular diseases,
blindness) complications, diabetic people need to maintain
their blood glucose within an acceptable range.
Big advances have been made in the recent years to help dia-
betic people in their daily life. Continuous glucose monitoring
(CGM) devices, such as the FreeStyle Libre [2], make possible
to track the glucose level throughout days and nights without
having to rely on the inconvenient use of lancets. Besides,
in combination with CGM devices, we are witnessing a rise
of coaching applications for diabetes such as the application
mySugr [3], which has been approved by the Food & Drug
Administration (FDA) in the United States. In the other hand,
bariatric surgery has been shown to induce a 10-year remission
rate of type 2 diabetes of 36% [4]. Finally, since 2016, the first
artificial pancreas, the MiniMed 670G, has been available in
the United States [5].
One of the biggest research area of interest is the prediction
of future glucose values. For a diabetic patient, knowing
accurately his future glycemia is undoubtedly valuable as it
can be used to avoid getting into the hypo-/hyperglycemia
ranges by modifying his behavior (e.g., by taking insulin shots
or by eating sugar).
Currently, the focus of glucose predictive models is heavily
in favor of data-driven techniques, where the patient’s glucose,
carbohydrate (CHO) intake and insulin injection past values
are used to forecast future glucose values. While the autore-
gressive (AR) model and its different variations are the most
traditionally used models in the field [6], they have fallen out
of favor for more complex regression models.
In particular, Zecchin et al. showed that using meal in-
formation improves the forecasting of glucose by using a
Feedforward Neural Network (FFNN) [7]. Recurrent Neural
Networks (RNN) is a class of artificial neural network (ANN)
made for time-series forecasting and have been used by
Daskalaki et al. to built a hypoglycemia early-warning system
[8]. While RNN present some limitations (e.g., the vanishing
gradient problem), novel types of the RNN cell have been
engineered and recently tried out to predict future glucose
values, such as the Long Short-Term Memory (LSTM) unit
by Mirshekarian et al. [9]. Extreme Learning Machine (ELM)
is another type of ANN that is quite popular nowadays thanks
to its ability to provide relatively good generalization with
close to no training time [10], [11].
Meanwhile, models that use the kernel method, also known
as the kernel trick, to map the initial space of observations into
a higher dimension space, have shown interesting results when
used to predict future glucose values. Georga et al. and Khan
et al. investigated the usability of Support Vector Regression
(SVR) in forecasting blood glucose [12], [13]. Besides, De
Paula et al. used Reinforcement Learning alongside with
Gaussian Processes (GP) to predict future glucose levels and
include the predictions in a decision-based system aiming at
regulating blood glucose [14].
However, those advances are hindered by several factors.
Because of their sensitive nature, diabetes-related data used
in studies are not made available to other researchers. This
leads every research team to collect its own data and building
their studies around them. Since most of the studies do not
share the same data, they cannot compare to each other. The
field needs comparative studies that give objective insights on
the performances of the models. In 2012, Daskalaki et al. led
a study aiming at comparing two AR models and a FFNN,
which ends up outperforming the former [15]. Meanwhile,
in 2015, Zarkogianni et al., compared four different models
they have investigated in previous studies, namely a FFNN
model, a linear regression model, a Self-Organizing Map and a
neuro-fuzzy network with wavelets [16]. Finally, also in 2015,
Georga et al. evaluated hybrid glucose predictive models that
combine regression models (SVR or GP) and feature ranking
algorithms [17].
Nowadays, it is still unclear how the most trending models
relate to each other in terms of performances. In this study,
we compare six of the most promising glucose predictive
models, namely a FFNN, a RNN with LSTM units, an ELM
neural network, a SVR model and two GP models. To address
this goal, we first describe the data flow, from its simulation
using the Type 1 Diabetes Metabolic Simulator software to the
implementation of the models. Then, we discuss the results of
the models obtained by evaluating them with two different
metrics. Finally, we conclude by providing our takeaways and
some guidelines for future studies.
II. METHODS
This section presents the whole methodology that has been
used to compare the predictive models. First, we explain how
we obtain our experimental data. Then, we go through the
preprocessing of the data and the building of the predictive
models. Finally, we discuss the evaluation metrics that have
been used in this study. Figure 1 illustrates this methodology.
A. Data Simulation
The T1DMS software [18] is a type-1 virtual diabetic
patients simulator that has been accepted as a substitute to
clinical testing by the FDA [19] and that has been extensively
used in the glucose prediction research field [7], [14], [20]–
[22].
In this study, 10 in-silico type-1 diabetic children (repre-
senting the most challenging diabetic population) underwent
the following open-loop experiment:
• 3-meal daily scenario, where the quantity and the timing
of each meal have been randomized to account for the
variability of real-life situations. More specifically, the
timings have been sampled from normal distributions
centered at 7h, 13h and 20h respectively and with a
variance of 0.5. As for the quantities (CHO intakes in
g), the normal distributions were centered at 40g, 85g
and 60g with a variance of 0.5 times the mean quantity.
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Fig. 1. Data flow diagram, from its simulation to the evaluation of the models.
• An insulin bolus is taken at the start of a meal. The
value of the bolus is taken uniformly between 0.7 and 1.3
times the patient’s optimal bolus given his carbohydrate-
to-insulin ratio.
• Basal insulin is constant and optimal (computed by the
simulator).
Similar scenarios have been used in the past few years [7],
[15], [22]. The major difference between our simulation and
others is the length of the simulation. While most simulations
last only a few days, we simulated 29 days of data. This serves
the purpose of enhancing the generalization of the models by
avoiding overfitting.
In the end, for every patient, the simulation outputs three
different time-series with a sampling frequency of 60 Hz:
glucose values, carbohydrate intakes and insulin boluses over
time.
B. Data Preprocessing
1) Data Rearrangement: First, we divided the 29-day long
time-series into day-long subsets. Then, we expanded every
daily subset with the data of the previous day to account for
the prediction horizon (30 minutes) and the data history (60
minutes) used in the models. Finally we discarded the first
day as it is mostly used to warm up the simulator. We end up
having 28 subsets of 1530 samples-long time-series. Figure 2
illustrates this process.
2) 3-way Data Splitting: Half of the subsets, the training
set, is used to train the models. A quarter, the evaluation set,
is used to tune the hyperparameters of the models. Finally,
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Fig. 2. Data rearrangement: from the 29-day long time-series, 28 subsets are created.
the remaining quarter, the testing set, is used to evaluate the
final model. We note that, even-though this kind of splitting
is a common procedure in Machine Learning, it has not been
used in the past in glucose prediction (a simpler training and
testing sets split is relatively common, though).
3) Standardization: The training set is standardized (zero-
mean and unit variance) and the same transformation is then
applied to the evaluation and testing sets.
C. Glucose Predictive Models
This subsection goes through all the models that have been
implemented. The training and optimization of the models
have been personalized to the patient.
1) Feedforward Neural Network (FFNN): The network is
made of 4 hidden layers of respectively 128, 64, 32 and 16
neurons. Apart from the last neuron, whose activation function
is linear, every neuron uses the Scaled Exponential Linear Unit
(SELU), which is the Exponential Linear Unit (ELU) with
an optimized value of α [23]. All the weights are initialized
using a coarse model trained on one of the children. This
serves the purpose of speeding up the training process of
the remaining children. The model is fine-tuned to the given
patient using the Adam optimizer with the Mean Squared Error
loss function, mini-batches of size 1500, an initial learning rate
of 10−3 and a decay of 10−4. To avoid the slight overfitting
encountered during the training of the models, we add up a L2
penalty to the weights and made use of early stopping. Alpha-
dropout (specific to the use of the SELU activation function)
has been tried out with no perceptible improvement. Also, the
SELU activation function, not used so far in glucose prediction
studies, has shown to work really well with better training
time and performances compared to more classical activation
functions (e.g., tanh, ReLU).
2) Long Short-Term Memory Recurrent Neural Network
(LSTM): The LSTM network is made of one recurrent layer
of 64 LSTM units. The network has been unrolled 60 times to
account for an history of 60 minutes. As for the FFNN model,
the weights are initialized to coarse values fitted on one of
the children. The model is then fine-tuned using the Adam
optimizer with the Mean Squared Error loss function, mini-
batches of size 500 and an initial learning rate of 10−2. As
for the amount of regularization used during the training, we
added a L2 penalty to the weights (10−4), used early stopping
and recurrent dropout (rate of 0.5). Since an increase in the
number of hidden layers or hidden neurons did not yield better
results, we stuck to a rather simple network.
3) Extreme Learning Machine (ELM): ELM networks are
quite simple to tune as we only need to adjust the number of
neurons in the single hidden layer and their activation function
[24]. The logistic activation function seemed to be the one to
work the best for us. We applied a L2 penalty (100.0) to the
weights to reduce the impact of overfitting. While continuously
adding more neurons improved the performances, we chose
to stop at 20160 neurons (which is the number of training
samples) as the increase in performance was not significant
afterwards.
4) Support Vector Regression (SVR): The SVR model has
been implemented using the radial basis function (RBF) kernel
(defined in Equation 1, with x and x′ being two input
vectors). The kernel’s coefficient (γ) has been personalized
and optimized by grid search from the initial [10−2, 101] range.
The parameter ǫ models the ǫ-tube within which no penalty
is associated to the training loss function. While the penalty
is also personalized and optimized within a specific range
([10−5, 10−2]), ǫ has been fixed to 10−3. Lower values of ǫ
made the model unable to fit the training data while greater
values yielded worse results.
k(x, x′) = exp(−γ‖x− x′‖2) (1)
5) Gaussian Process (GP) Regression: As for the SVR
model, GP models are traditionally used with a RBF kernel in
glucose prediction studies [17]. However, we found out that
using a dot-product (DP) kernel (defined in Equation 2, with
x and x′ being two input vectors) was way more effective.
Therefore, we implement both versions of Gaussian Process
regression: one with a RBF kernel (GP-RBF) and one with a
DP kernel (GP-DP).
k(x, x′) = σ2
0
+ x · x′ (2)
The RBF kernel has been fixed with a value of γ of 0.5 as
changing the values did not impact the results. As for the DP
kernel, the value of σ0 has also been fixed to a value of 0.01
for the same reason.
In order to help our models to fit the training data, we
added noise to the observations, represented by the value α
that is added to the diagonal of the kernel matrix during fitting.
More noise implies an easier fit but also worse results, so we
personalized and optimized its value in the [10−2, 101] range.
D. Performance Metrics
We evaluate the performances of the models using nested
cross-validation [25], doing permutations of the training, eval-
uation and testing sets splitting (which is described in Section
II-B2). A first cross-validation between the training and the
evaluation sets is used to tune the hyperparameters of the
models. Then, the tuned and fitted models are evaluated with
a second round of cross-validation with the testing set.
A lot of different evaluation metrics have been used through-
out the years [26]. We have settled down with the two most
significant ones : the Root Mean Squared Error (RMSE) and
the Continuous Glucose Error Grid Analysis (CG-EGA).
1) Root Mean Squared Error: The RMSE (defined in Equa-
tion 3, with y being the true values and yˆ being the predicted
values) is the standard metric to measure the performance of
a glucose predictive model. It has the advantage of being
a single value metric making comparison between models
straightforward. It can also be used as the loss function during
the training stage (e.g., when training neural networks). And,
compared to other similar metrics (e.g., the Mean Absolute
Error), it penalizes bigger errors more, which is preferable in
glucose prediction since big errors, even when they are rare,
can have disastrous consequences.
RMSE(y, yˆ) =
√√√√ 1
n
n∑
i=1
(yi − yˆi)2 (3)
2) Continuous Glucose-Error Grid Analysis: The CG-
EGA, initially introduced to measure the clinical acceptability
of Continuous Glucose Monitoring (CGM) devices [27], sees a
lot of use in the evaluation of glucose predictive models [26].
It is made of two different evaluation grids: the Point-Error
Grid Analysis (P-EGA) and the Rate-Error Grid Analysis (R-
EGA). With the P-EGA, depending on the true glucose value,
predictions are assigned to clinical acceptability areas, from
A to E (i.e. good to bad). As for the R-EGA, the idea is the
same but we focus on rates of change instead of focusing
on the point-values themselves. The CG-EGA is simply the
Cartesian product of the P-EGA and the R-EGA. In order to
appreciate the CG-EGA, it is simplified by giving each cell
a measure of its clinical acceptability, depending of the true
state of the patient’s glycemia. A cell can then either contain
accurate predictions (AP), benign errors (BE) or erroneous
predictions (EP).
III. RESULTS
The experimental results have been reported in Table I
which depicts, in terms of average RMSE and CG-EGA across
the children, the performance of the six models described in
section II-C.
With the biggest RMSE and, in most glycemia areas in the
CG-EGA, the biggest amount of EP, the ELM model comes
out to be the worst in our study.
In terms of RMSE, the SVR, the FFNN and the GP-DP
models stand out from the other models by making predictions
the closest to the actual glucose values, with the GP-DP model
being the best of the three.
As for the clinical acceptability of the models, the con-
clusions depend on the glycemia range. In the range of
euglycemia (where the true glucose value is between 70 mg/dL
and 180 mg/dL), all the models manage to make acceptable
predictions with a minimum of 0.09% (SVR and LSTM) and a
maximum of 1% (ELM) of EP. However, in the hypoglycemia
range (true value below 70 mg/dL), the ELM and the GP-RBF
models show clinically unacceptable results with a significant
number of EP. In the hyperglycemia range, the ELM and the
FFNN models show also unacceptable results with a high
number of EP and BE. Overall, the LSTM, SVR and GP-DP
models show stable good results across the whole CG-EGA
table.
Figure 3 gives the reader the opportunity to visualize the
predictions of the models against the true glucose values for
one of the children during a specific day, starting at 0h00 and
ending at 23h59. The three peaks in the graph that extend
into the hyperglycemia range represent the postprandial rise
of glucose.
IV. DISCUSSION
By showing high EP in at least one CG-EGA range, the
ELM, the GP-RBF and the FFNN to some extent, do not make
safe predictions for the diabetic patients. However, there is
no clear winner among the remaining three models. While
GP-DP presents the best RMSE and best CG-EGA in the
hypoglycemia range, it is surpassed by the LSTM and SVR
models in the remaining areas of the CG-EGA, with both
being, respectively, the best model in the euglycemia and the
best model in the hyperglycemia range. We also note that
the GP-DP model has generally higher AP standard deviation
values compared to the other models in the CG-EGA. With
higher standard deviations, the GP-DP results are shown to be
less stable across the diabetic children population, which is not
preferable considering potential future use of such predictive
models into the whole real diabetic population.
In a completely different perspective, our study shows the
usefulness of using the CG-EGA to assess the performances
of the models and not relying solely on the RMSE metric.
To illustrate this idea, we can compare the results of the
FFNN and the LSTM models. As we can see in Table I,
while the FFNN model has the second lowest RMSE, its CG-
EGA results in the hyperglycemia range make it clinically
TABLE I
PERFORMANCES OF GLUCOSE PREDICTION MODELS WITH MEAN AND STANDARD DEVIATION ACROSS THE CHILDREN.
Models RMSE
CG-EGA
Hypoglycemia Euglycemia Hyperglycemia
AP BE EP AP BE EP AP BE EP
ELM 11.24 (2.74) 96.01 (4.24) 0.13 (0.11) 3.85 (4.30) 92.95 (2.94) 6.04 (2.90) 1.01 (0.58) 75.95 (5.09) 18.58 (4.07) 5.47 (1.84)
GP-RBF 7.84 (2.51) 94.82 (12.23) 0.07 (0.08) 5.11 (12.26) 97.15 (1.43) 2.74 (1.42) 0.12 (0.05) 97.53 (1.62) 1.95 (1.29) 0.51 (0.42)
LSTM 7.08 (1.53) 99.01 (0.72) 0.12 (0.12) 0.87 (0.71) 97.46 (1.28) 2.45 (1.27) 0.09 (0.02) 97.79 (1.07) 1.79 (0.94) 0.42 (0.20)
SVR 5.92 (2.19) 99.22 (0.59) 0.04 (0.08) 0.74 (0.55) 97.29 (1.55) 2.61 (1.54) 0.09 (0.03) 97.99 (1.65) 1.72 (1.49) 0.29 (0.18)
FFNN 5.43 (1.84) 99.09 (0.51) 0.09 (0.07) 0.81 (0.49) 95.29 (2.15) 4.30 (2.09) 0.40 (0.17) 88.60 (2.25) 9.32 (1.87) 2.08 (0.54)
GP-DP 5.16 (1.96) 99.37 (1.66) 0.03 (0.05) 0.61 (0.45) 96.87 (1.66) 2.86 (1.57) 0.27 (0.14) 95.63 (3.40) 3.34 (2.77) 1.03 (0.75)
AP: Accurate Prediction (in %); BE: Benign Error (in %); EP: Erroneous Prediction (in %)
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Fig. 3. Daily glucose predictions as a function of time for a child during a specific day.
unacceptable. If we look into the details of the FFNN’s CG-
EGA (Figure 4), compared to those of the LSTM model
(Figure 5) from the same child during the same day, we can
understand why. In both the P-EGA and the R-EGA figures, a
perfect prediction is represented by the line in the middle of
the A zones. In both P-EGA grids, while most predictions are
in the A zone, we can see that FFNN predictions are closer
to true values compared to those made by the LSTM model
(this difference is reflected by the difference in RMSE between
both models). In the other hand, the R-EGA figures show us
that the predicted rates of change of the FFNN model are
much more spread out inside the grid. For a model to have
overall good CG-EGA results, it needs to perform well in
the P-EGA and in the R-EGA grids at the same time. The
FFNN model, while being one of the best point predictive
models (RMSE or P-EGA), has trouble estimating precisely
and consistently the glucose variations. We think that the
LSTM model manages to have good CG-EGA results despite
not being one of the best RMSE thanks to the inherent nature
of the algorithm. RNN, especially those based on LSTM units,
make use of the sequential nature of the data to remember
important observations to compute coherent predictions.
Finally, the results highlight some limitations of the CG-
EGA. First, as it is not usually trained on (given its complex
nature), algorithms which are only trained to compute good
point predictions (e.g. FFNN) may not succeed the clinical
acceptability test because it involves rates of change predic-
tions. Second, the CG-EGA fails at discriminating models that
have more or less the same results (namely LSTM, SVR and
GP-DP). We should note that, rather than from the CG-EGA
itself, it comes from the common simplification made from it
(the AP, BE and EP categories).
V. CONCLUSION
In this paper we studied six of the most trending and
promising glucose predictive models. We compared a FFNN,
a LSTM RNN, a ELM neural network, a SVR model, and
two GP models, one with a RBF kernel and the other with
a DP kernel. While the RMSE has been used to measure the
accuracy of the predictions, the CG-EGA has been used to
provide a measure of the clinical acceptability of the models.
The GP-DP model is a novel improvement of GP models,
traditionally used with a RBF kernel in the context of glucose
prediction.
The analysis of the results showed that only the LSTM,
SVR and GP-DP have overall satisfactory results, each of
them having its own strength. In particular, while the GP-
DP model presents the best RMSE as well as the best clinical
acceptability in the hypoglycemia range, the LSTM and SVR
models excel, respectively, in the euglycemia range and in the
hyperglycemia range.
Besides, we highlighted the limitations of the evaluation
methodology currently used in the field of glucose prediction.
While the CG-EGA covers the RMSE weakness by providing
a way of evaluating the clinical acceptability of the models,
it is not perfect as it cannot be trained on and, given the
common simplification used to report the results, cannot help
discriminating between the best models.
This study makes us identify new approaches to tackle
the problem of predicting future glucose values of diabetic
patients such as improving the way we evaluate the models
or combining them into a single predictor (through fusion
algorithms for instance) which would take advantage of their
different strengths.
Finally, in the future, we aim at conducting this study on
the other diabetic populations (i.e., adolescents, adults) and for
longer prediction horizons (e.g., 60 or 120 minutes) to see if
we can generalize our results and findings.
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Fig. 4. P-EGA and R-EGA of the FFNN model of a child for a specific day. For every prediction, AP, BE and EP markers are computed by combining the
P-EGA and the R-EGA into the CG-EGA.
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